Tobira Therapeutics Inc (TBRA)-Medical Equipment-Deals and Alliances Profile

Region:North America

Author(s):

Product Code:GDME140409D

Download Sample Report download
Buy the Full ReportStarting from $250
Published on

April 2017

Total pages

24

Table of Content

Download Sample Report download
Buy the Full ReportStarting from $250

About the Report

About the Report

Tobira Therapeutics Inc (Tobira), formerly Regado Biosciences, Inc, which develops and commercializes therapies for the treatment of to treat non-alcoholic steatohepatitis (NASH) and other liver diseases, inflammation, fibrosis and HIV. Its pipeline products include Cenicriviroc (CVC) and Evogliptin (EVO). The company's lead product candidate, cenicriviroc, is a proprietary immunomodulator which is used to treat diseases such as HIV-1, and others. Evogliptin is an orally bioavailable, selective dipeptidyl peptidase-4 inhibitor which prevents the breakdown of incretin hormones glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). The company seeks partnership for in-licensing and combination therapy development for the fibrosis, inflammation and HIV. Tobira is headquartered in San Francisco, California, the US.

Tobira Therapeutics Inc (TBRA)-Medical Equipment-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

Products

Table of Contents

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 3

List of Figures 4

Tobira Therapeutics Inc, Medical Equipment, Deals By Year, 2011 to YTD 2017 5

Tobira Therapeutics Inc, Medical Equipment Deals By Type, 2011 to YTD 2017 6

Tobira Therapeutics Inc, Medical Equipment, Deals By Region, 2011 to YTD 2017 7

Tobira Therapeutics Inc, Medical Equipment, Deals By Market, 2011 to YTD 2017 8

Tobira Therapeutics Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 9

Tobira Therapeutics Inc, Medical Equipment, Deal Details 10

Venture Financing 10

Regado Biosciences Raises US$51 Million In Series E Financing 10

Regado Biosciences Secures US$11.6 Million In Financing 11

Equity Offering 12

Regado Biosciences Completes Public Offering Of Shares For US$60 Million 12

Regado Biosciences Completes Private Placement Of Shares For US$20 Million 13

Regado Biosciences Completes Underwriters' Exercise Of Over-Allotment Option For IPO For US$43 Million 14

Acquisition 15

Allergan Acquires Tobira Therapeutics in Tender Offer 15

Tobira Therapeutics Inc-Key Competitors 18

Key Employees 19

Locations And Subsidiaries 20

Head Office 20

Recent Developments 21

Financial Announcements 21

Aug 09, 2016: Tobira Therapeutics Reports Second Quarter 2016 Financial and Business Results 21

May 09, 2016: Tobira Therapeutics Reports First Quarter 2016 Financial and Business Results 22

Mar 03, 2016: Tobira Therapeutics Reports Fourth Quarter 2015 Financial and Year-End Business ResultsC 23

Appendix 24

Methodology 24

About GlobalData 24

Contact Us 24

Disclaimer 24


List of Figure

List of Figures

Tobira Therapeutics Inc, Medical Equipment, Deals by Type, 2011 to YTD 2017 1

Tobira Therapeutics Inc, Medical Equipment, Deals By Year, 2011 to YTD 2017 1

Tobira Therapeutics Inc, Medical Equipment, Deals By Region, 2011 to YTD 2017 1

Tobira Therapeutics Inc, Medical Equipment, Deals By Market, 2011 to YTD 2017 1

Tobira Therapeutics Inc, Medical Equipment, Deals By Year, 2011 to YTD 2017 5

Tobira Therapeutics Inc, Medical Equipment, Deals by Type, 2011 to YTD 2017 6

Tobira Therapeutics Inc, Medical Equipment, Deals By Region, 2011 to YTD 2017 7

Tobira Therapeutics Inc, Medical Equipment, Deals by Market, 2011 to YTD 2017 8


List of Table

List of Tables

Tobira Therapeutics Inc, Medical Equipment, Key Facts, 2015 1

Tobira Therapeutics Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 1

Tobira Therapeutics Inc, Medical Equipment, Deals By Year, 2011 to YTD 2017 5

Tobira Therapeutics Inc, Medical Equipment Deals By Type, 2011 to YTD 2017 6

Tobira Therapeutics Inc, Medical Equipment, Deals By Region, 2011 to YTD 2017 7

Tobira Therapeutics Inc, Deals By Market, 2011 to YTD 2017 8

Tobira Therapeutics Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 9

Regado Biosciences Raises US$51 Million In Series E Financing 10

Regado Biosciences Secures US$11.6 Million In Financing 11

Regado Biosciences Completes Public Offering Of Shares For US$60 Million 12

Regado Biosciences Completes Private Placement Of Shares For US$20 Million 13

Regado Biosciences Completes Underwriters' Exercise Of Over-Allotment Option For IPO For US$43 Million 14

Allergan Acquires Tobira Therapeutics in Tender Offer 15

Tobira Therapeutics Inc, Key Competitors 18

Tobira Therapeutics Inc, Key Employees 19

You can also purchase parts of this report.
Do you want to check out a section wise price list?
Get Price Break-up

Why Buy From US?

RRR
Refine Robust Result (RRR) Framework

What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story

reach
Our Reach Is Unmatched

We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.

Research
Shifting the Research Paradigm

While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.

Insite
More Insights-Better Decisions

With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.

Trust
Transparency and Trust

Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.

support
Round the Clock Support

If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.

Why Client Choose Us?

400000+ Reports in repository
150+ Consulting project a year
100+ Analysts
8000+ Client Queries in 2022